Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson’s Disease: Past, Present, and Future
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson’s Disease: Past, Present, and Future
Authors
Keywords
-
Journal
Journal of Parkinsons Disease
Volume 12, Issue 2, Pages 477-493
Publisher
IOS Press
Online
2021-12-22
DOI
10.3233/jpd-212976
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The effect of monoamine oxidase-B inhibitors on the alleviation of depressive symptoms in Parkinson’s disease: meta-analysis of randomized controlled trials
- (2021) Yao Hsien Huang et al. Therapeutic Advances in Psychopharmacology
- SURINPARK: Safinamide for Urinary Symptoms in Parkinson’s Disease
- (2021) Ana Gómez-López et al. Brain Sciences
- Safinamide Improves Non-Motor Symptoms Burden in Parkinson’s Disease: An Open-Label Prospective Study
- (2021) Diego Santos García et al. Brain Sciences
- Selegiline reduces daytime sleepiness in patients with Parkinson's disease
- (2021) Marco Gallazzi et al. Brain and Behavior
- Effects of safinamide on non-motor, cognitive, and behavioral symptoms in fluctuating Parkinson’s disease patients: a prospective longitudinal study
- (2021) Rosa De Micco et al. NEUROLOGICAL SCIENCES
- Group-based music intervention in Parkinson’s disease – findings from a mixed-methods study
- (2020) Petra Pohl et al. CLINICAL REHABILITATION
- Aberrant Tonic Inhibition of Dopaminergic Neuronal Activity Causes Motor Symptoms in Animal Models of Parkinson’s Disease
- (2020) Jun Young Heo et al. CURRENT BIOLOGY
- Rasagiline and selegiline modulate mitochondrial homeostasis, intervene apoptosis system and mitigate α-synuclein cytotoxicity in disease-modifying therapy for Parkinson’s disease
- (2020) Makoto Naoi et al. JOURNAL OF NEURAL TRANSMISSION
- Identifying and responding to fatigue and apathy in Parkinson’s disease: a review of current practice
- (2020) Claudia Lazcano-Ocampo et al. Expert Review of Neurotherapeutics
- Initiation of pharmacological therapy in Parkinson's disease: when, why, and how
- (2020) Rob M A de Bie et al. LANCET NEUROLOGY
- A Spanish Consensus on the Use of Safinamide for Parkinson’s Disease in Clinical Practice
- (2020) Javier Pagonabarraga et al. Brain Sciences
- Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson’s disease: a multiple treatment comparison meta-analysis
- (2020) Caroline D. Binde et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: A randomized, double-blind, placebo-controlled, phase II/III study
- (2020) Nobutaka Hattori et al. PARKINSONISM & RELATED DISORDERS
- Long-term safety and efficacy of safinamide as add-on therapy in levodopa-treated Japanese patients with Parkinson's disease with wearing-off: Results of an open-label study
- (2020) Yoshio Tsuboi et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial
- (2020) Giovanni Abbruzzese et al. Journal of Parkinsons Disease
- Long-term safety and efficacy of adjunctive rasagiline in levodopa-treated Japanese patients with Parkinson’s disease
- (2019) Nobutaka Hattori et al. JOURNAL OF NEURAL TRANSMISSION
- Monoamine oxidase-B inhibitors as potential neurotherapeutic agents: An overview and update
- (2019) Rati Kailash Prasad Tripathi et al. MEDICINAL RESEARCH REVIEWS
- Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review
- (2019) Klaus Seppi et al. MOVEMENT DISORDERS
- Polycaprolactone-based neurotherapeutic delivery of rasagiline targeting behavioral and biochemical deficits in Parkinson’s disease
- (2019) N. Kanwar et al. Drug Delivery and Translational Research
- Long-term, open-label, phase 3 study of rasagiline in Japanese patients with early Parkinson’s disease
- (2019) Nobutaka Hattori et al. JOURNAL OF NEURAL TRANSMISSION
- Parkinson's Disease and Parkinsonism
- (2019) Michael T Hayes AMERICAN JOURNAL OF MEDICINE
- The Up-Regulation of Oxidative Stress as a Potential Mechanism of Novel MAO-B Inhibitors for Glioblastoma Treatment
- (2019) Guya Diletta Marconi et al. MOLECULES
- Clinical and methodological challenges for assessing freezing of gait: Future perspectives
- (2019) Martina Mancini et al. MOVEMENT DISORDERS
- Monoamine Oxidases (MAOs) as Privileged Molecular Targets in Neuroscience: Research Literature Analysis
- (2019) Andy Wai Kan Yeung et al. Frontiers in Molecular Neuroscience
- Parkinson's disease: Mechanisms, translational models and management strategies
- (2019) Chand Raza et al. LIFE SCIENCES
- Sleep in Parkinson’s disease
- (2019) Ambra Stefani et al. NEUROPSYCHOPHARMACOLOGY
- Non-motor symptoms burden, mood, and gait problems are the most significant factors contributing to a poor quality of life in non-demented Parkinson's disease patients: Results from the COPPADIS Study Cohort
- (2019) García D. Santos et al. PARKINSONISM & RELATED DISORDERS
- Neuroprotective Effects of Rasagiline in Parkinson's Disease: A Regional Cerebral Blood Flow Study
- (2019) Jooyeon Jamie Im et al. JOURNAL OF NEUROIMAGING
- Danshensu attenuates scopolamine and amyloid-β-induced cognitive impairments through the activation of PKA-CREB signaling in mice
- (2019) Ho Jung Bae et al. NEUROCHEMISTRY INTERNATIONAL
- A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson's disease
- (2018) C. D. Binde et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Safinamide: a new hope for Parkinson’s disease?
- (2018) Fábio G. Teixeira et al. DRUG DISCOVERY TODAY
- Design, synthesis and biochemical evaluation of novel multi-target inhibitors as potential anti-Parkinson agents
- (2018) Simone Carradori et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Rasagiline improves polysomnographic sleep parameters in patients with Parkinson's disease: a double-blind, baseline-controlled trial
- (2018) W. Schrempf et al. EUROPEAN JOURNAL OF NEUROLOGY
- MAO inhibitors and their wider applications: a patent review
- (2018) Simone Carradori et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial
- (2018) Albert C Ludolph et al. LANCET NEUROLOGY
- International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease
- (2018) Susan H. Fox et al. MOVEMENT DISORDERS
- Efficacy and safety of adjunctive rasagiline in Japanese Parkinson's disease patients with wearing-off phenomena: A phase 2/3, randomized, double-blind, placebo-controlled, multicenter study
- (2018) Nobutaka Hattori et al. PARKINSONISM & RELATED DISORDERS
- Neuropathology of Parkinson disease
- (2018) Dennis W. Dickson PARKINSONISM & RELATED DISORDERS
- Safinamide effect on sleep disturbances and daytime sleepiness in motor fluctuating Parkinson's disease patients: A validated questionnaires-controlled study
- (2018) Claudio Liguori et al. PARKINSONISM & RELATED DISORDERS
- Effective treatment of restless legs syndrome by safinamide in Parkinson's disease patients
- (2018) Claudio Liguori et al. SLEEP MEDICINE
- Clinical Profile of Chinese Long-Term Parkinson’s Disease Survivors With 10 Years of Disease Duration and Beyond
- (2018) Qian Sun et al. Aging and Disease
- Adjunct rasagiline to treat Parkinson’s disease with motor fluctuations: a randomized, double-blind study in China
- (2018) Zhenxin Zhang et al. Translational Neurodegeneration
- Coumarin-dithiocarbamate hybrids as novel multitarget AChE and MAO-B inhibitors against Alzheimer’s disease: Design, synthesis and biological evaluation
- (2018) Qi He et al. BIOORGANIC CHEMISTRY
- Different generations of type-B monoamine oxidase inhibitors in Parkinson’s disease: from bench to bedside
- (2018) Marika Alborghetti et al. Current Neuropharmacology
- Monoamine oxidase isoenzymes: genes, functions and targets for behavior and cancer therapy
- (2018) Jean C. Shih JOURNAL OF NEURAL TRANSMISSION
- Fatigue in Parkinson's disease: A systematic review and meta-analysis
- (2018) Mattia Siciliano et al. MOVEMENT DISORDERS
- Rasagiline monotherapy in early Parkinson's disease: A phase 3, randomized study in Japan
- (2018) Nobutaka Hattori et al. PARKINSONISM & RELATED DISORDERS
- Current drugs and potential future neuroprotective compounds for Parkinson`s disease
- (2018) Ivan Carrera et al. Current Neuropharmacology
- Safinamide Modulates Striatal Glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia
- (2018) F. Gardoni et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Efficacy of safinamide on non-motor symptoms in a cohort of patients affected by idiopathic Parkinson’s disease
- (2018) Maria Laura Ester Bianchi et al. NEUROLOGICAL SCIENCES
- Efficacy and safety of rasagiline in Chinese patients with early Parkinson’s disease: a randomized, double-blind, parallel, placebo-controlled, fixed-dose study
- (2018) Zhenxin Zhang et al. Translational Neurodegeneration
- Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson’s disease
- (2017) Thomas Müller Expert Opinion on Drug Metabolism & Toxicology
- Management of Parkinson Disease in 2017
- (2017) Michael S. Okun JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Efficacy of rasagiline and selegiline in Parkinson’s disease: a head-to-head 3-year retrospective case–control study
- (2017) Emanuele Cereda et al. JOURNAL OF NEUROLOGY
- A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's disease
- (2017) C. Warren Olanow et al. MOVEMENT DISORDERS
- Non-motor features of Parkinson disease
- (2017) Anthony H.V. Schapira et al. NATURE REVIEWS NEUROSCIENCE
- Parkinson’s disease: summary of updated NICE guidance
- (2017) Gabriel Rogers et al. BMJ-British Medical Journal
- Long-Term Effects of Safinamide on Mood Fluctuations in Parkinson’s Disease
- (2017) Carlo Cattaneo et al. Journal of Parkinsons Disease
- Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson’s Disease: An Analysis of NET-PD LS1
- (2017) Robert A. Hauser et al. Journal of Parkinsons Disease
- The MPTP Story
- (2017) J. William Langston Journal of Parkinsons Disease
- Parkinson’s disease: summary of updated NICE guidance
- (2017) Gabriel Rogers et al. BMJ-British Medical Journal
- Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations
- (2017) Anthony H. V. Schapira et al. JAMA Neurology
- Mitochondria and α-Synuclein: Friends or Foes in the Pathogenesis of Parkinson’s Disease?
- (2017) Gaia Faustini et al. Genes
- Levodopa in Parkinson’s Disease: Current Status and Future Developments
- (2017) Nicola Tambasco et al. Current Neuropharmacology
- Effects of rasagiline on freezing of gait in Parkinson's disease - an open-label, multicenter study
- (2016) Frantisek Cibulcik et al. BIOMEDICAL PAPERS-OLOMOUC
- The course of insomnia in Parkinson's disease
- (2016) Kangdi Zhu et al. PARKINSONISM & RELATED DISORDERS
- Inhibitory effect of traditional oriental medicine-derived monoamine oxidase B inhibitor on radioresistance of non-small cell lung cancer
- (2016) Beomseok Son et al. Scientific Reports
- Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson’s Disease Fluctuating Patients: Post hoc Analysesof Studies 016 and SETTLE
- (2016) Carlo Cattaneo et al. Journal of Parkinsons Disease
- The recommendations of Chinese Parkinson’s disease and movement disorder society consensus on therapeutic management of Parkinson’s disease
- (2016) Shengdi Chen et al. Translational Neurodegeneration
- A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson's disease patients
- (2015) P. Barone et al. EUROPEAN JOURNAL OF NEUROLOGY
- Rasagiline for the treatment of Parkinson’s disease: an update
- (2015) Fabrizio Stocchi et al. EXPERT OPINION ON PHARMACOTHERAPY
- Rasagiline and selegiline suppress calcium efflux from mitochondria by PK11195-induced opening of mitochondrial permeability transition pore: a novel anti-apoptotic function for neuroprotection
- (2015) Yuqiu Wu et al. JOURNAL OF NEURAL TRANSMISSION
- Parkinson's disease
- (2015) Lorraine V Kalia et al. LANCET
- Freezing of gait: a practical approach to management
- (2015) Jorik Nonnekes et al. LANCET NEUROLOGY
- Rasagiline for the symptomatic treatment of fatigue in Parkinson's disease
- (2015) Thien Thien Lim et al. MOVEMENT DISORDERS
- Neuroprotection by safinamide in the 6-hydroxydopamine model of Parkinson's disease
- (2015) Mona Sadeghian et al. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY
- Beneficial behavioral, neurochemical and molecular effects of 1-(R)-aminoindan in aged mice
- (2015) Felix Badinter et al. NEUROPHARMACOLOGY
- Rasagiline, a Suicide Inhibitor of Monoamine Oxidases, Binds Reversibly to α-Synuclein
- (2014) Joe Kakish et al. ACS Chemical Neuroscience
- Freezing of gait in Chinese patients with Parkinson Disease
- (2014) Ruwei Ou et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial
- (2014) PD MED Collaborative Group LANCET
- Improvingl-dopa therapy: The development of enzyme inhibitors
- (2014) Oscar S. Gershanik MOVEMENT DISORDERS
- Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease
- (2014) Robert A. Hauser et al. MOVEMENT DISORDERS
- Rasagiline effect on bladder disturbances in early mild Parkinson's disease patients
- (2014) L. Brusa et al. PARKINSONISM & RELATED DISORDERS
- Serotonin Toxicity Association with Concomitant Antidepressants and Rasagiline Treatment: Retrospective Study (STACCATO)
- (2014) Michel Panisset et al. PHARMACOTHERAPY
- Sleep and Circadian Rhythm Regulation in Early Parkinson Disease
- (2014) David P. Breen et al. JAMA Neurology
- Benefits of treatment with rasagiline for fatigue symptoms in patients with early Parkinson's disease
- (2013) F. Stocchi et al. EUROPEAN JOURNAL OF NEUROLOGY
- Efficacy and safety of rasagiline as an adjunct to levodopa treatment in Chinese patients with Parkinson's disease: a randomized, double-blind, parallel-controlled, multi-centre trial
- (2013) Lina Zhang et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- Selective MAO-B inhibitors: a lesson from natural products
- (2013) Simone Carradori et al. MOLECULAR DIVERSITY
- Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations
- (2013) Rupam Borgohain et al. MOVEMENT DISORDERS
- Rasagiline adjunct therapy in patients with Parkinson's disease: Post hoc analyses of the PRESTO and LARGO trials
- (2013) Lawrence W. Elmer PARKINSONISM & RELATED DISORDERS
- Comparison of oral and transdermal administration of rasagiline mesylate on human melanoma tumor growthin vivo
- (2012) Susan R. Meier-Davis et al. Cutaneous and Ocular Toxicology
- Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease
- (2012) A. H. V. Schapira et al. EUROPEAN JOURNAL OF NEUROLOGY
- Switch from selegiline to rasagiline is beneficial in patients with Parkinson’s disease
- (2012) Thomas Müller et al. JOURNAL OF NEURAL TRANSMISSION
- Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson’s disease
- (2011) F. Stocchi et al. EUROPEAN JOURNAL OF NEUROLOGY
- A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients
- (2011) Fabrizio Stocchi et al. MOVEMENT DISORDERS
- The Promise of Neuroprotective Agents in Parkinson?s Disease
- (2011) Stacey E. Seidl et al. Frontiers in Neurology
- The relationship between depression and regional cerebral blood flow in Parkinson’s disease and the effect of selegiline treatment
- (2010) K. Imamura et al. ACTA NEUROLOGICA SCANDINAVICA
- Orally Disintegrating Selegiline in Parkinson Patients With Dopamine Agonist-Related Adverse Effects
- (2010) Kelly E. Lyons et al. CLINICAL NEUROPHARMACOLOGY
- Long-Term Efficacy of Rasagiline in Early Parkinson's Disease
- (2010) Mark F. Lew et al. INTERNATIONAL JOURNAL OF NEUROSCIENCE
- The Anti-Parkinsonian Drug Selegiline Delays the Nucleation Phase of α-Synuclein Aggregation Leading to the Formation of Nontoxic Species
- (2010) Carolina A. Braga et al. JOURNAL OF MOLECULAR BIOLOGY
- Rasagiline: A novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity
- (2010) Orly Weinreb et al. PROGRESS IN NEUROBIOLOGY
- A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
- (2009) C. Warren Olanow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Monoamine oxidase inactivation: From pathophysiology to therapeutics☆
- (2008) Marco Bortolato et al. ADVANCED DRUG DELIVERY REVIEWS
- Elucidating the Mechanism of Action and Potential Interactions of MAO-B Inhibitors
- (2008) Jacquelyn L. Bainbridge et al. NEUROLOGIC CLINICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now